Lumira Ventures

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

Congruence Therapeutics is a biotechnology company focused on drug discovery for diseases associated with protein misfolding. By integrating computational and experimental approaches, the company develops novel small molecules aimed at treating rare diseases. Utilizing structural bioinformatics, computational chemistry, and machine learning, Congruence has established an in silico platform that facilitates the design and validation of pharmacological stabilizers. This innovative approach allows researchers to create targeted therapeutic options for conditions linked to protein misfolding, advancing the field of biotechnology and improving treatment outcomes for affected patients.

Developer of novel gene-editing technologies designed to treat diseases at the genetic level in cells inside the body. The company's technology consists of a dual-cleaving nuclease that can be delivered to cells to treat various genetic diseases, enabling customers to exploit the cell's naturally occurring DNA repair pathways through enhanced repair or predictable deletions.

OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.

OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Early stage biotechnology start-up developing next generation cytokine therapeutics

Thryv Therapeutics is a biopharmaceutical company focused on developing therapies for long QT syndrome, a genetic disorder characterized by prolonged ventricular repolarization, which can lead to life-threatening arrhythmias. The company's research centers on SGK-1, a regulator of sodium channels in heart cells, which is implicated in the overactivity associated with long QT syndrome. By targeting this kinase, Thryv aims to address the underlying causes of the disorder and improve treatment options for affected patients. Based in Laval, Canada, the company is committed to advancing its pipeline to enhance patient outcomes in this critical area of cardiovascular health.

BioTheryX, Inc. is a biopharmaceutical company based in Chappaqua, New York, that specializes in the development of therapies for hematological malignancies and other diseases. The company focuses on restoring protein homeostasis through innovative approaches such as Protein Homeostatic Modulators, which are small molecular glue cereblon binders with significant therapeutic potential. Additionally, BioTheryX is advancing targeted protein degradation technologies, including PROTACs, which utilize dual ligands to facilitate the degradation of specific proteins. The company also offers BTX-A51, an oral small molecule that acts as a multi-kinase inhibitor to target leukemic stem cells and suppress key oncogenic gene transcription. Founded in 2007, BioTheryX aims to expedite the delivery of effective therapies to patients with unmet medical needs by leveraging enhanced biology-driven models and clinically proven translational approaches.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

AmacaThera Inc. is a biotechnology company based in Toronto, Canada, established in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology aimed at enhancing medical treatments. This technology is designed to localize and sustain drug delivery, thereby improving patient outcomes across various therapeutic areas. AmacaThera's hydrogel consists of a reversible and fast-gelling physical blend of hyaluronan and methylcellulose, which liquefies under force. This unique formulation assists healthcare providers in reducing post-operative pain for patients, showcasing the potential of AmacaThera's approach in addressing significant medical needs.

Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada. It was founded in 2010 and is headquartered in Houston, Texas.

Notch Therapeutics Inc. is an immune cell therapy company based in Toronto, Canada, focused on developing gene-edited allogenic T cell therapies for cancer treatment. Established in 2018, the company utilizes an induced pluripotent stem cell (iPSC) platform that enables precise control of Notch signaling. This innovative technology addresses key limitations in cell therapy development by allowing for the design and manufacture of a consistent supply of therapeutic T cells. Notch Therapeutics specializes in iPSC AlloCAR therapy products aimed at treating conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, enabling healthcare professionals to engineer stem cells tailored to the specific biological challenges presented by complex diseases.

XyloCor Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Established in 2013 and based in Newtown Square, Pennsylvania, the company is working on innovative treatments such as XC001, an investigational gene therapy aimed at patients suffering from refractory angina who have limited treatment options, and XC002, which targets cardiac tissue regeneration in individuals with compromised heart function due to past heart attacks. XyloCor's approach involves stimulating the formation of new coronary blood vessels to improve blood supply to areas of the heart that are inadequately perfused, thereby offering potential pain relief and improved outcomes for patients who have exhausted conventional pharmacologic therapies.

Cyrano Therapeutics, Inc., founded in 2014 and headquartered in Washington, D.C., develops therapeutic solutions aimed at addressing taste and smell disorders. The company's primary offering is an intranasal product, CYR-001, which repurposes the approved molecule Theophylline to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, the treatment demonstrated significant efficacy, with eight out of ten patients showing notable improvements within two weeks and no reported side effects. In addition to the therapy, Cyrano Therapeutics provides a diagnostic kit to assess and quantify the severity of sensory loss, which can assist healthcare providers, particularly otolaryngologists, in managing care for affected individuals, including cancer patients undergoing chemotherapy who may experience sensory changes.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

IMV Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies and vaccines for infectious diseases, including COVID-19. Utilizing its proprietary delivery platform, the company targets immune cells within the human body to enhance their ability to attack cancer cells. Its lead candidate, DPX-Survivac, is a targeted T cell therapy that has shown promise in multiple Phase 1 and 1b trials for late-stage ovarian cancer and relapsed/refractory DLBCL. DPX-Survivac is currently undergoing Phase 2 clinical trials across six cancer types and is being evaluated in combination with Keytruda. IMV is also progressing with a DPX-based vaccine for COVID-19, developed in collaboration with experts in infectious diseases, and is working on a vaccine targeting the respiratory syncytial virus strain A. Founded in 2000 and based in Dartmouth, Canada, the company was previously known as Immunovaccine Inc. before rebranding in 2018.

IMV Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies and vaccines for infectious diseases, including COVID-19. Utilizing its proprietary delivery platform, the company targets immune cells within the human body to enhance their ability to attack cancer cells. Its lead candidate, DPX-Survivac, is a targeted T cell therapy that has shown promise in multiple Phase 1 and 1b trials for late-stage ovarian cancer and relapsed/refractory DLBCL. DPX-Survivac is currently undergoing Phase 2 clinical trials across six cancer types and is being evaluated in combination with Keytruda. IMV is also progressing with a DPX-based vaccine for COVID-19, developed in collaboration with experts in infectious diseases, and is working on a vaccine targeting the respiratory syncytial virus strain A. Founded in 2000 and based in Dartmouth, Canada, the company was previously known as Immunovaccine Inc. before rebranding in 2018.

Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance, enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.

AmacaThera Inc. is a biotechnology company based in Toronto, Canada, established in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology aimed at enhancing medical treatments. This technology is designed to localize and sustain drug delivery, thereby improving patient outcomes across various therapeutic areas. AmacaThera's hydrogel consists of a reversible and fast-gelling physical blend of hyaluronan and methylcellulose, which liquefies under force. This unique formulation assists healthcare providers in reducing post-operative pain for patients, showcasing the potential of AmacaThera's approach in addressing significant medical needs.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraines. The company's primary product candidate, STS101, is a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine mesylate. This medication is designed for self-administration using a pre-filled, single-use nasal delivery device. Currently, STS101 is undergoing Phase III clinical trials, marking a significant step in its development process. Founded in 2016 and based in South San Francisco, California, Satsuma Pharmaceuticals aims to provide effective solutions for individuals suffering from acute migraine attacks.

Bardy Diagnostics, Inc. is a medical device company that specializes in the development and manufacturing of cardiac monitoring solutions, primarily focused on arrhythmia detection. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight, discreet cardiac patch that can be worn comfortably for up to seven days, even during physical activities like exercise or showering. The CAM is designed with a unique hourglass shape to enhance comfort, particularly for female patients. Complementing the monitor is the BDxCONNECT patient management system, which allows healthcare providers to create and manage patient reports efficiently. By utilizing innovative P-wave centric ECG detection technology, Bardy Diagnostics aims to improve clinical management and outcomes for patients and their physicians. Founded in 2013, the company is headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections.Gladius is a disruptive platform technology play, capable of developing multiple novel drug candidates

Pediapharm is the ONLY pediatric specialty pharmaceutical company in Canada, providing sales and marketing expertise for the pediatric market segment. Through its network of 2,000 pediatricians and 5,000 pharmacies, Pediapharm's key objectives are to partner with healthcare entities around the world and bring NEW innovative or existing OTC and Rx pediatric products to the Canadian market.

Osteopathy Quebec is the result of the merger between the Register of Osteopaths of Quebec and the Quebec Association Of Osteopathic.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.

KalGene Inc. is a Canadian company focused on developing precision medicine aimed at treating Alzheimer's disease and cancer. Established in 2006 and based in Candiac, the company collaborates with leading clinician-scientists and academic institutions across North America and Europe. KalGene specializes in creating targeted therapeutics and companion diagnostics that utilize a personalized medicine approach. This methodology seeks to predict patient responses to specific therapies based on their unique biological profiles, allowing for tailored treatment plans. By emphasizing individualized care, KalGene's therapeutics aim to improve both clinical outcomes and overall quality of life, while addressing safety concerns associated with traditional treatments.

Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.

KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.

Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.

Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

KalGene Inc. is a Canadian company focused on developing precision medicine aimed at treating Alzheimer's disease and cancer. Established in 2006 and based in Candiac, the company collaborates with leading clinician-scientists and academic institutions across North America and Europe. KalGene specializes in creating targeted therapeutics and companion diagnostics that utilize a personalized medicine approach. This methodology seeks to predict patient responses to specific therapies based on their unique biological profiles, allowing for tailored treatment plans. By emphasizing individualized care, KalGene's therapeutics aim to improve both clinical outcomes and overall quality of life, while addressing safety concerns associated with traditional treatments.

Engage Therapeutics, based in Summit, New Jersey, is a biopharmaceutical company focused on developing innovative therapies for individuals experiencing uncontrolled epileptic seizures. The company's lead product, Staccato® alprazolam, is a handheld drug-device combination that utilizes an established FDA-approved delivery system to administer alprazolam, an FDA-approved benzodiazepine. This product aims to provide immediate rescue therapy for active seizures, offering a potential solution for patients and their caregivers. In a Phase 2a proof of concept study, Staccato alprazolam demonstrated efficacy in reducing seizures in a photosensitivity model. Engage Therapeutics plans to advance this product into further clinical development through a 505(b)(2) regulatory pathway, positioning it as a promising option for seizure management.

Stellar Biotechnologies, previously an independent biotechnology company, specialized in the research, development, and commercialization of keyhole limpet hemocyanin (KLH) protein, primarily serving the immunotherapy and immunodiagnostic markets. Based in Port Hueneme, California, the company offered KLH in various grades and formulations, catering to the needs of biotechnology and pharmaceutical firms, academic institutions, clinical research organizations, and research centers across Europe, North America, and Asia. KLH is an immune-stimulating protein utilized in the production of immunotherapies and as a carrier molecule in diagnostic products. In June 2019, Stellar Biotechnologies was acquired by Edesa Biotech Inc. through a reverse merger transaction, integrating its expertise in KLH protein with Edesa's focus on developing innovative treatments for dermatological and anorectal diseases.

Edesa Biotech is a clinical-stage biotechnology company dedicated to developing innovative treatments for dermatological and anorectal diseases, with a particular focus on inflammatory and immune-related conditions. The company aims to provide safer and more effective alternatives to topical steroids, which can have undesirable side effects. Its lead product candidate, EB01, is a non-steroidal anti-inflammatory treatment specifically designed for allergic contact dermatitis, having shown statistically significant improvements in various clinical studies. Additionally, Edesa is advancing its second candidate, EB05, a monoclonal antibody therapy intended for hospitalized COVID-19 patients. Through its commitment to research and development, Edesa Biotech seeks to address unmet medical needs in its targeted therapeutic areas.

Osteopathy Quebec is the result of the merger between the Register of Osteopaths of Quebec and the Quebec Association Of Osteopathic.

Forbius, also known as Formation Biologics, is a clinical-stage company focused on designing and developing biotherapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, Forbius specializes in creating agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. The company aims to provide highly active inhibitors of these validated pathways, utilizing its expertise in biology and protein engineering technologies to develop novel therapeutic options. Through their innovative approach, Forbius seeks to significantly improve patient outcomes and transform the treatment landscape for challenging diseases.

Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.

KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

Opsens Inc. specializes in the development, manufacture, installation, and sale of fiber optic sensors, catering to various sectors including interventional cardiology, oil and gas, and industrial applications. The company operates through two primary segments: Medical and Industrial. The Medical segment focuses on physiological measurements such as fractional flow reserve (FFR) and provides miniature optical sensors for pressure and temperature measurement, essential for coronary artery stenosis diagnosis. It also licenses its optical sensor technology. The Industrial segment creates fiber optic sensing solutions applicable in diverse fields such as life sciences, energy, defense, and civil engineering. Notable products include OptoWire, an advanced optical pressure guidewire for coronary artery disease, and a range of fiber optic sensors for measuring temperature, pressure, strain, and displacement. Opsens distributes its products through a direct sales force and partnerships with distributors in the United States, Japan, Canada, and other international markets. Headquartered in Québec, Canada, Opsens is recognized for its high-accuracy sensors that are particularly beneficial in clinical environments.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

Osteopathy Quebec is the result of the merger between the Register of Osteopaths of Quebec and the Quebec Association Of Osteopathic.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.

This national mobile wellness rewards initiative harnesses the public’s affinity for popular loyalty points, the convenience of smart phone technology and Canadians’ natural desire to lead healthier lives. It is this unique combination that results in such a powerful “nudge” platform – in support of a healthier

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.

First Aid Shot Therapy is a company specializing in clinical beverages aimed at addressing acute and chronic health needs. Founded in 2010 and headquartered in Burlingame, California, it offers a variety of easy-to-swallow, single-dose products that deliver fast-acting relief for common everyday symptoms such as hangovers, pain, sleep issues, colds, allergies, and heartburn. The company's focus is on providing effective solutions that help consumers manage their symptoms quickly and conveniently.

Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.

Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections.Gladius is a disruptive platform technology play, capable of developing multiple novel drug candidates

Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Osteopathy Quebec is the result of the merger between the Register of Osteopaths of Quebec and the Quebec Association Of Osteopathic.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.

Forbius, also known as Formation Biologics, is a clinical-stage company focused on designing and developing biotherapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, Forbius specializes in creating agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. The company aims to provide highly active inhibitors of these validated pathways, utilizing its expertise in biology and protein engineering technologies to develop novel therapeutic options. Through their innovative approach, Forbius seeks to significantly improve patient outcomes and transform the treatment landscape for challenging diseases.

Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, that specializes in the design and development of non-fusion motion preservation systems aimed at treating degenerative diseases of the cervical and lumbar spine. Founded in 2003, the company offers the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both of which replicate the anatomical and biomechanical properties of natural intervertebral discs. This innovative approach allows for the incorporation of an artificial nucleus and annulus, providing surgeons with a practical option for disc replacement. Spinal Kinetics distributes its products through a network of distributors across multiple countries, including Australia, Canada, several European nations, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.

Aptose Biosciences Inc. is a clinical-stage biotechnology company based in Toronto, Canada, specializing in the discovery and development of personalized cancer therapies. The company focuses on addressing unmet medical needs in oncology, particularly through its clinical programs targeting blood cancers. One of its key products, APTO-253, is currently undergoing a Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Additionally, Aptose has partnered with CrystalGenomics, Inc. to develop CG026806, a small molecule in Phase 1a/b trials for similar blood cancers. Another collaboration with OHM Oncology involves the development and commercialization of APL-581 for hematologic malignancies. Founded in 1986 and formerly known as Lorus Therapeutics Inc., Aptose continues to build a portfolio of innovative cancer treatments, emphasizing safety and efficacy.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.

Vendorlink.ca specializes in web-based vendor management solutions tailored for the healthcare sector. The platform enables hospitals to enforce their policies while training and monitoring vendors to ensure compliance with patient safety and privacy standards. Vendorlink.ca offers a comprehensive suite of tools designed to manage various aspects of vendor relationships, including tracking credentials, activities, and behaviors. Additionally, the company employs a dedicated team to verify each vendor's credentials before they are published on the vendor's profile. For vendors, Vendorlink.ca acts as a third-party credentialing system, facilitating immediate access to their credentials for hospitals, thus streamlining the vendor management process in healthcare settings.

Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

USystems specializes in the design, development, and manufacturing of advanced technology solutions in two primary sectors: medical imaging and data center infrastructure. In the medical field, the company creates innovative breast ultrasound systems that aid radiologists in detecting breast cancer, particularly in women with dense breast tissue, by providing detailed 3D ultrasound images for improved visualization. In the realm of data centers, USystems manufactures cooling systems that enhance sustainability while reducing noise and heat. Their offerings include air-cooled and soundproof rapid deployment micro data centers equipped with intelligent features, such as real-time alarms and optional security monitoring, to safeguard IT equipment and optimize operational efficiency. Through its cutting-edge designs and state-of-the-art manufacturing processes, USystems is committed to delivering high-quality solutions that address critical challenges in both healthcare and information technology.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

Forbius, also known as Formation Biologics, is a clinical-stage company focused on designing and developing biotherapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, Forbius specializes in creating agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. The company aims to provide highly active inhibitors of these validated pathways, utilizing its expertise in biology and protein engineering technologies to develop novel therapeutic options. Through their innovative approach, Forbius seeks to significantly improve patient outcomes and transform the treatment landscape for challenging diseases.

USystems specializes in the design, development, and manufacturing of advanced technology solutions in two primary sectors: medical imaging and data center infrastructure. In the medical field, the company creates innovative breast ultrasound systems that aid radiologists in detecting breast cancer, particularly in women with dense breast tissue, by providing detailed 3D ultrasound images for improved visualization. In the realm of data centers, USystems manufactures cooling systems that enhance sustainability while reducing noise and heat. Their offerings include air-cooled and soundproof rapid deployment micro data centers equipped with intelligent features, such as real-time alarms and optional security monitoring, to safeguard IT equipment and optimize operational efficiency. Through its cutting-edge designs and state-of-the-art manufacturing processes, USystems is committed to delivering high-quality solutions that address critical challenges in both healthcare and information technology.

USystems specializes in the design, development, and manufacturing of advanced technology solutions in two primary sectors: medical imaging and data center infrastructure. In the medical field, the company creates innovative breast ultrasound systems that aid radiologists in detecting breast cancer, particularly in women with dense breast tissue, by providing detailed 3D ultrasound images for improved visualization. In the realm of data centers, USystems manufactures cooling systems that enhance sustainability while reducing noise and heat. Their offerings include air-cooled and soundproof rapid deployment micro data centers equipped with intelligent features, such as real-time alarms and optional security monitoring, to safeguard IT equipment and optimize operational efficiency. Through its cutting-edge designs and state-of-the-art manufacturing processes, USystems is committed to delivering high-quality solutions that address critical challenges in both healthcare and information technology.

Pathfinder Therapeutics

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.